Compare Boston Scientific Corporation (BSX) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Meta Platforms Inc — how do they compare? Boston Scientific Corporation trades at $43.16 (market cap $66.37B), while Meta Platforms Inc trades at $679.17 (market cap $1.68T). The key difference: Meta Platforms Inc is far larger — about 25.3× Boston Scientific Corporation's market cap, and Meta Platforms Inc pays a 0.32% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | META | |
|---|---|---|
Market Cap | $66.37B | $1.68T |
Sector | Health | Media |
52-Week High | $108.14 | $790.00 |
52-Week Low | $42.63 | $525.72 |
Enterprise Value | $75.94B | $1.68T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
META stock trades at $674.78, up 2.75% today, reflecting strong momentum near its recent highs. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $10.44 significantly exceeding expectations. Revenue growth remains solid, reaching $201.0B in 2025, while profitability metrics like a 32.84% net income margin and 32.93% ROE highlight operational efficiency. Technical indicators show a bullish trend with support at $655 and resistance at $678, though RSI levels suggest potential overbought conditions.
The outlook for META is positive, driven by AI innovations like Muse Spark and strong analyst consensus with a $815.44 price target. However, risks include ongoing litigation, such as the Massachusetts youth addiction lawsuit, and high capital expenditures in AI infrastructure. Investors should weigh the company's growth trajectory against regulatory and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
